Redefining Targeted Cancer Delivery
Our proprietary IgM-based technology harnesses the unique biology of naturally occurring IgM antibodies to deliver therapeutic payloads to tumors selectively. By enhancing tumor localization and retention, we aim to improve the precision and effectiveness of cancer therapies while building on a clinically validated antibody class.
Unlocking the Power of IgM Biology
Despite significant advances in antibody therapeutics, current formats often face limitations in tumor targeting and payload delivery. IgM offers a differentiated approach designed to overcome these challenges through its unique biological properties.
IgM: A Structural and Functional Advantage
The pentameric structure of IgM provides up to ten antigen-binding sites, resulting in high-avidity interactions with target tumor cells. This distinctive structure enhances tumor binding, accumulation, and retention while supporting efficient payload delivery, creating new opportunities for more precise cancer therapeutics.
Mechanism of action
Delivering Therapies Where They Matter Most
Our antibody delivers cancer drugs directly to tumors, increasing drug accumulation where it matters most while reducing exposure to healthy tissues. As a combination approach, it is designed to improve the efficacy and safety of existing oncology therapies.
Designed for combination use, our IgM approach enhances the delivery of existing cancer therapies by increasing tumor targeting and accumulation. This strategy has the potential to improve efficacy, reduce systemic exposure, and accelerate clinical translation by building on established treatment regimens.
Early Technical Feasibility Supported by Published Evidence
Multiple independent publications have demonstrated the potential of IgM to enhance tumor targeting, retention, and therapeutic outcomes. Consistent findings across diverse models, payloads, and research groups provide strong scientific support for the biological advantages of IgM in targeted drug delivery.
Explore the science, supporting evidence, and proof-of-concept data behind our approach.
Expanding the Potential of Targeted Cancer Therapies
Positioned at the intersection of targeted drug delivery and precision oncology, our approach addresses a rapidly expanding market opportunity. By enhancing the performance of existing therapeutics, we aim to create value across multiple oncology indications while utilizing established treatment paradigms.
A Capital-Efficient Path to Value Creation
We create value through early partnerships, milestone-driven execution, and scalable oncology opportunities, enabling efficient development and multiple paths to commercialization.
We welcome discussions with investors, pharmaceutical partners, and collaborators who share our vision of advancing next-generation oncology therapies. Together, we aim to unlock the potential of IgM biology to enable safer, more effective drug delivery and improve outcomes for millions of cancer patients worldwide.